LOS ANGELES--(BUSINESS WIRE)--Sep. 4, 2012--
Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing
in oncology, today announced that President and Chief Executive Officer
Steven A. Kriegsman and Vice President of Business Development David J.
Haen will present a business update at the Rodman & Renshaw 14th
Annual Global Investment Conference on Tuesday, September 11 at 11:15
a.m. Eastern time (8:15 a.m. Pacific time) in the Starlight Center of
the Waldorf=Astoria in New York City.
A webcast of the presentation will be available on the Company’s website
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development
company specializing in oncology. The CytRx oncology pipeline includes
two programs in clinical development for cancer indications: aldoxorubicin
(formerly known as INNO-206) and tamibarotene.
With its tumor-targeted doxorubicin conjugate aldoxorubicin, CytRx has
initiated an international Phase 2b clinical trial as a treatment for
soft tissue sarcomas, has completed its Phase 1b/2 clinical trial
primarily in the same indication, recently initiated both a Phase 2
trial for patients with advanced pancreatic ductal adenocarcinomas and a
Phase 1b study of aldoxorubicin in combination with doxorubicin in
patients with advanced solid tumors, and plans to meet with the FDA in
the second half of 2012 to discuss a potential Phase 3 pivotal trial as
a therapy for patients with soft tissue sarcomas whose tumors have
progressed following treatment with chemotherapy. Tamibarotene is being
tested in a double-blind, placebo-controlled, international Phase 2b
clinical trial in patients with non-small-cell lung cancer, and is in a
Phase 2 clinical trial as a treatment for acute promyelocytic leukemia
(APL). The Company completed its evaluation of a third drug candidate, bafetinib,
in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic
lymphocytic leukemia (B-CLL), and plans to seek a partner for further
development of bafetinib. For more information about the Company, visit www.cytrx.com.
Source: CytRx Corporation
Legend Securities, Inc.